• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本一起新冠肺炎集群感染后医护人员的临床和流行病学特征以及汉方药方剂——小柴胡汤和葛根汤的影响:一项回顾性队列研究。

Clinical and epidemiological features of healthcare workers after a coronavirus disease 2019 cluster infection in Japan and the effects of Kampo formulas-Hochuekkito and Kakkonto: A retrospective cohort study.

机构信息

Kampo Clinical Center, Department of General Internal Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Osaka, Japan.

出版信息

Medicine (Baltimore). 2022 Jul 15;101(28):e29748. doi: 10.1097/MD.0000000000029748.

DOI:10.1097/MD.0000000000029748
PMID:35839019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11132327/
Abstract

It is expected that a low-toxicity natural compound like Kampo formulas would exhibit a preventive effect on COVID-19, in a global outbreak of coronavirus disease 2019 (COVID-19). Although the biological properties and safety of the representative Kampo, Hochuekkito (HET), and Kakkonto (KKT) have been confirmed in various animal model experiments and clinical studies, and in a few human studies to induce biological effects on various infectious diseases without significant toxicity, it is unclear whether HET and KKT are safe and effective for COVID-19 prevention. We summarized the clinical characteristics of HCWs and the preventive effects of HET and KKT. We performed a retrospective, single-center, cohort study that included 175 HCWs (aged 21-77 years) from a total number of 217 in a hospital with a history of COVID-19 cluster infection. In total, 175 HCWs were tested for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies. We identified 27 patients (median age: 49 ± 10.7 years) who were diagnosed with COVID-19. The patients in the group that had a body mass index ≥ 25 had a high COVID-19 infection risk, while those in the group with a Kampo formula adherence rate ≥ 40% had a low COVID-19 risk. Patients in the group with an adherence rate ≥ 40%, as well as those in the current alcohol consumption group, were at a low risk of developing severe COVID-19. In conclusion, HET and KKT may have prevented the onset or worsening of COVID-19, which could be clinically used. Obesity might have increased the patients' susceptibility to COVID-19 and the disease severity.

摘要

预计像汉方药方剂这样的低毒性天然化合物将对 2019 年冠状病毒病(COVID-19)的全球大流行产生预防作用。虽然代表性汉方 Hochuekkito(HET)和 Kakkonto(KKT)的生物学特性和安全性已在各种动物模型实验和临床研究中得到证实,并且在少数诱导对各种传染病产生生物学作用而无明显毒性的人体研究中得到证实,但尚不清楚 HET 和 KKT 是否对 COVID-19 的预防安全有效。我们总结了 HCWs 的临床特征以及 HET 和 KKT 的预防作用。我们进行了一项回顾性、单中心队列研究,该研究纳入了一家有 COVID-19 集群感染史的医院的 175 名 HCWs(年龄 21-77 岁)。共有 175 名 HCWs 接受了严重急性呼吸冠状病毒 2(SARS-CoV-2)抗体检测。我们共发现 27 名 COVID-19 患者(中位年龄:49±10.7 岁)。体重指数≥25 的患者 COVID-19 感染风险较高,而汉方方剂服用率≥40%的患者 COVID-19 风险较低。汉方方剂服用率≥40%的患者以及目前饮酒的患者患严重 COVID-19 的风险较低。总之,HET 和 KKT 可能预防了 COVID-19 的发病或恶化,这可能在临床上得到应用。肥胖可能增加了患者对 COVID-19 的易感性和疾病严重程度。

相似文献

1
Clinical and epidemiological features of healthcare workers after a coronavirus disease 2019 cluster infection in Japan and the effects of Kampo formulas-Hochuekkito and Kakkonto: A retrospective cohort study.日本一起新冠肺炎集群感染后医护人员的临床和流行病学特征以及汉方药方剂——小柴胡汤和葛根汤的影响:一项回顾性队列研究。
Medicine (Baltimore). 2022 Jul 15;101(28):e29748. doi: 10.1097/MD.0000000000029748.
2
Immunological and Preventive Effects of Hochuekkito and Kakkonto Against Coronavirus Disease in Healthcare Workers: A Retrospective Observational Study.补中益气汤和葛根汤对医护人员冠状病毒病的免疫及预防作用:一项回顾性观察研究。
Front Pharmacol. 2021 Nov 18;12:766402. doi: 10.3389/fphar.2021.766402. eCollection 2021.
3
A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).一项针对使用汉方药预防 COVID-19 的多中心、随机对照试验(RCT)的研究方案的结构化总结。(日本综合传染病防治研究:IMJEDI P1 研究)
Trials. 2021 Jan 6;22(1):23. doi: 10.1186/s13063-020-04939-2.
4
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.一项由日本综合传染病管理(IMJEDI 研究-RCT)开展的多中心、随机对照临床试验,评估了汉方药加味抗感煎剂(kakkonto with shosaikotokakikyosekko)在缓解 COVID-19 轻症和中度患者症状和预防重症方面的作用:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 2;21(1):827. doi: 10.1186/s13063-020-04746-9.
5
Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI Study-observation).常规和汉方药治疗轻中度 COVID-19:日本传染病综合管理(IMJEDI 研究-观察)的多中心回顾性观察研究。
Intern Med. 2023 Jan 15;62(2):187-199. doi: 10.2169/internalmedicine.0027-22. Epub 2022 Nov 2.
6
Contribution of traditional Japanese Kampo medicines, kakkonto with shosaikotokakikyosekko, in treating patients with mild-to-moderate coronavirus disease 2019: Further analysis of a multicenter, randomized controlled trial.探讨传统日本汉方药“葛根汤加味方”治疗轻中度 2019 冠状病毒病患者的作用:一项多中心、随机对照试验的进一步分析。
J Infect Chemother. 2023 Nov;29(11):1054-1060. doi: 10.1016/j.jiac.2023.07.013. Epub 2023 Jul 26.
7
Epidemiological and clinical characteristics of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare workers in Hubei Province, China.湖北省医护人员中严重急性呼吸冠状病毒 2 型(SARS-CoV-2)感染的流行病学和临床特征。
Infect Control Hosp Epidemiol. 2021 Aug;42(8):924-930. doi: 10.1017/ice.2020.1321. Epub 2020 Nov 18.
8
Serology suggests adequate safety measures to protect healthcare workers from COVID-19 in Shiga Prefecture, Japan.血清学表明,在日本滋贺县采取充分的安全措施可保护医护人员免受 COVID-19 感染。
PLoS One. 2022 Jun 24;17(6):e0270334. doi: 10.1371/journal.pone.0270334. eCollection 2022.
9
Application of Kampo Medicines for Treatment of General Fatigue Due to Long COVID.汉方药物在治疗长新冠一般疲劳中的应用。
Medicina (Kaunas). 2022 May 28;58(6):730. doi: 10.3390/medicina58060730.
10
The experience of the health care workers of a severely hit SARS-CoV-2 referral Hospital in Italy: incidence, clinical course and modifiable risk factors for COVID-19 infection.意大利一家严重受 SARS-CoV-2 影响的转诊医院医护人员的经历:COVID-19 感染的发生率、临床过程和可改变的危险因素。
J Public Health (Oxf). 2021 Apr 12;43(1):26-34. doi: 10.1093/pubmed/fdaa195.

引用本文的文献

1
Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro.汉防己甲素对 SARS-CoV-2 木瓜蛋白酶样蛋白酶活性的体外抑制作用。
J Nat Med. 2024 Jun;78(3):784-791. doi: 10.1007/s11418-024-01788-0. Epub 2024 Mar 21.

本文引用的文献

1
Immunological and Preventive Effects of Hochuekkito and Kakkonto Against Coronavirus Disease in Healthcare Workers: A Retrospective Observational Study.补中益气汤和葛根汤对医护人员冠状病毒病的免疫及预防作用:一项回顾性观察研究。
Front Pharmacol. 2021 Nov 18;12:766402. doi: 10.3389/fphar.2021.766402. eCollection 2021.
2
Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan.在日本的一项大型 COVID-19 患者队列中,入院时严重程度和住院期间疾病进展的危险因素。
BMJ Open. 2021 Jun 15;11(6):e047007. doi: 10.1136/bmjopen-2020-047007.
3
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study.
在英格兰 690 万人中,体重指数与 COVID-19 严重程度的关联:一项前瞻性、基于社区的队列研究。
Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-359. doi: 10.1016/S2213-8587(21)00089-9. Epub 2021 Apr 28.
4
Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India.吸烟、饮酒及其他导致有症状新冠病毒病与无症状严重急性呼吸综合征冠状病毒2感染的风险因素:一项来自印度拉贾斯坦邦西部的病例对照研究
Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):820-831. doi: 10.1093/trstmh/traa172.
5
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.新冠肺炎出院患者 6 个月的后果:一项队列研究。
Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.
6
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.患有糖尿病的人感染 COVID-19 疾病的风险和风险因素:苏格兰全人群的队列研究。
Lancet Diabetes Endocrinol. 2021 Feb;9(2):82-93. doi: 10.1016/S2213-8587(20)30405-8. Epub 2020 Dec 23.
7
BMI as a Risk Factor for Clinical Outcomes in Patients Hospitalized with COVID-19 in New York.BMI 作为纽约因 COVID-19 住院患者临床结局的危险因素。
Obesity (Silver Spring). 2021 Feb;29(2):279-284. doi: 10.1002/oby.23076. Epub 2020 Dec 23.
8
Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan.日本 2019 年冠状病毒病(COVID-19)住院患者的临床流行病学:COVID-19 登记日本报告。
Clin Infect Dis. 2021 Dec 6;73(11):e3677-e3689. doi: 10.1093/cid/ciaa1470.
9
Persistent Symptoms in Patients After Acute COVID-19.急性 COVID-19 后患者的持续症状。
JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
10
Prevalence and Clinical Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During an Early Phase of the Pandemic.在大流行早期的 2 家荷兰医院中,有症状的 COVID-19 医护人员的患病率和临床表现。
JAMA Netw Open. 2020 May 1;3(5):e209673. doi: 10.1001/jamanetworkopen.2020.9673.